MedTrace Logo

Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage

NCT01866241 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1140

Last updated 2014-09-08

No results posted yet for this study

Summary

Null hypothesis: 10 IU Oxytocin is better than sublingual misoprostol 600µg in management of third stage of labor Alternative hypothesis: Sublingual misoprostol 600µg is non- inferior to 10 IU oxytocin and will not be more than 6% worse \[than 10 IU oxytocin\] in management of third stage of labor

Conditions

  • Post Partum Hemorrhage

Interventions

DRUG

Misoprostol

Is a prostaglandin

Sponsors & Collaborators

  • Makerere University

    collaborator OTHER

  • University Ghent

    collaborator OTHER

  • Mbarara University of Science and Technology

    lead OTHER

Principal Investigators

  • Amon Agaba, PhD · Mbarara University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-09-30
Completion
2013-10-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01866241 on ClinicalTrials.gov